| Not Yet Recruiting | Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fi NCT07441408 | Bristol-Myers Squibb | Phase 3 |
| Not Yet Recruiting | Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases NCT07459205 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Enrolling By Invitation | Telomeres Length in Israeli Fibrotic ILD Patients NCT06885515 | Barzilai Medical Center | — |
| Recruiting | Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases NCT07464132 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis NCT07396467 | The First Affiliated Hospital with Nanjing Medical University | — |
| Not Yet Recruiting | Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects NCT07229716 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 |
| Active Not Recruiting | The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary NCT06912659 | Boehringer Ingelheim | — |
| Completed | A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects NCT06939504 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 |
| Active Not Recruiting | Interstitial Lung Disease Exacerbations Study NCT06685874 | Royal Devon and Exeter NHS Foundation Trust | — |
| Recruiting | Advanced Imaging for Pulmonary Fibrosis NCT06532071 | Peter Caravan | Phase 2 |
| Completed | A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Mult NCT06746064 | Chiesi Farmaceutici S.p.A. | Phase 1 |
| Recruiting | Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis NCT06162884 | University of California, Los Angeles | — |
| Recruiting | Routine vs On-demand ECMO for Lung Transplantation NCT06615492 | Centre hospitalier de l'Université de Montréal (CHUM) | N/A |
| Recruiting | P4O2 ILD Extension NCT06644144 | Amsterdam UMC, location VUmc | — |
| Recruiting | Implementation of Home Monitoring in Patients With Pulmonary Fibrosis NCT06883448 | Erasmus Medical Center | N/A |
| Enrolling By Invitation | Physical Exercise Program for Adults With Diffuse Interstitial Lung Disease in a Pulmonary Rehabilitation Cont NCT07061873 | Universidad de La Frontera | N/A |
| Terminated | Frequency-time Analysis of Pathological Lung Sounds: Detection and Quantification of Pathological Sounds in Pa NCT06399094 | Groupe Hospitalier de la Region de Mulhouse et Sud Alsace | — |
| Not Yet Recruiting | Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis Patients NCT05899556 | Power Life Sciences Inc. | — |
| Recruiting | Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Bre NCT06528418 | ChromX Health | — |
| Recruiting | A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease NCT06122233 | University of Sydney | N/A |
| Unknown | Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19 NCT05890573 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis NCT06329401 | Avalyn Pharma Inc. | Phase 2 |
| Unknown | A Retrospective Study of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis NCT06275295 | China-Japan Friendship Hospital | — |
| Recruiting | Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis NCT06251687 | China-Japan Friendship Hospital | N/A |
| Withdrawn | Safety of Nintedanib in Real World in China NCT05676112 | Boehringer Ingelheim | — |
| Unknown | Exercise Tolerance and Lower-limb Muscle Power in Patients With Chronic Respiratory Disease NCT06124859 | Lille Catholic University | N/A |
| Enrolling By Invitation | Illness Expectations in Pulmonary Fibrosis NCT06327360 | Fondazione Don Carlo Gnocchi Onlus | — |
| Completed | Evaluating the Potential of Large Language Models for Respiratory Disease Consultations NCT06457269 | North Sichuan Medical College | N/A |
| Recruiting | Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease NCT06304207 | MGH Institute of Health Professions | N/A |
| Active Not Recruiting | Clinical Study of Allogeneic Fat Decellularized Active Protein in the Treatment of Pulmonary Fibrosis NCT05883293 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | EARLY_Phase 1 |
| Completed | Metabolomic Biomarkers Evaluation in Pulmonary Fibrosis NCT06974799 | University of Campania Luigi Vanvitelli | — |
| Unknown | Pulmonary Rehabilitation in Non-chronic Obstructive Pulmonary Disease Patients. NCT05174741 | Riphah International University | N/A |
| Completed | Oxygen Nanobubble Drink Impact on Exercise in Pulmonary Fibrosis NCT05711290 | University of Oxford | N/A |
| Completed | A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects NCT05740475 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 |
| Recruiting | Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases NCT06189820 | Erasme University Hospital | Phase 2 |
| Unknown | Pulmonary Fibrosis Lung Sounds Study NCT05771740 | Royal Devon and Exeter NHS Foundation Trust | — |
| Unknown | Diagnostic and Prognostic Model of Pulmonary Fibrosis After COVID-19 Pneumonia and Mechanism Study NCT05719038 | Kunming Medical University | — |
| Completed | A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device NCT05670587 | Boehringer Ingelheim | N/A |
| Suspended | Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19 NCT05387239 | Vitti Labs, LLC | Phase 2 |
| Completed | Comparison of Pulmonary Telerehabilitation and Physical Activity Recommendations in Patients With Post Covid F NCT05299333 | Istanbul University - Cerrahpasa | N/A |
| Recruiting | Pulmonary Fibrosis Foundation Community Registry NCT05382572 | Pulmonary Fibrosis Foundation | — |
| Completed | 68Ga-FAPI PET/CT to Detect Ongoing Fibroblast Activity in Post-acute COVID-19 NCT05981885 | University Medical Center Groningen | — |
| Completed | A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subj NCT05331300 | Lassen Therapeutics 1 PTY LTD | Phase 1 / Phase 2 |
| Completed | Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF NCT05330312 | Vicore Pharma AB | N/A |
| Completed | Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Ho NCT04979884 | Alexandria University | Phase 3 |
| Unknown | 99mTc-HFAPI SPECT/CT in Pulmonary Fibrosis NCT05859763 | Peking Union Medical College Hospital | N/A |
| Completed | Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286 NCT05180162 | Thomas Hope | Phase 1 |
| Recruiting | Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT NCT05121779 | Peking Union Medical College Hospital | Phase 1 |
| Recruiting | FAPI PET for Lung Fibrosis NCT05365802 | University of California, Los Angeles | EARLY_Phase 1 |
| Completed | Dyspnea and Idiopathic Pulmonary Fibrosis NCT04864990 | University Hospital, Lille | — |
| Enrolling By Invitation | Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs NCT04930289 | Paragonix Technologies | — |
| Terminated | Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases NCT04119115 | Corewell Health East | — |
| Recruiting | Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland NCT06702228 | Royal College of Surgeons, Ireland | — |
| Terminated | The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Heal NCT04638517 | The University of Queensland | Phase 2 |
| Active Not Recruiting | Post Acute Sequelae of COVID-19 NCT04964115 | Vanderbilt University Medical Center | — |
| Recruiting | Interstitial Lung Disease Research Unit Biobank NCT05392881 | University of Kansas Medical Center | — |
| Unknown | COVID-19 Pathophysiology of Long Term Implications NCT04813575 | King Faisal Specialist Hospital & Research Center | N/A |
| Active Not Recruiting | Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis NCT04948203 | University of Chicago | Phase 2 / Phase 3 |
| Completed | Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions NCT04987606 | Imperial College London | — |
| Completed | Multiple Breath Washout as a Method for Diagnosing Lung Diseases NCT06179342 | Wissenschaftliches Institut Bethanien e.V | — |
| Completed | The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects. NCT06160440 | Guangzhou JOYO Pharma Co., Ltd | Phase 1 |
| Unknown | The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19 NCT04805086 | Guy's and St Thomas' NHS Foundation Trust | Phase 1 / Phase 2 |
| Unknown | Fibrosing ILD Biomarkers That Rule Acceleration NCT05635032 | Universidade do Porto | — |
| Unknown | Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression NCT04136223 | Hospital do Coracao | — |
| Active Not Recruiting | Advancing Prevention of Pulmonary Fibrosis NCT04564183 | University of Colorado, Denver | — |
| Completed | Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest NCT04170062 | Johns Hopkins University | N/A |
| Terminated | A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypert NCT03267108 | Bellerophon Pulse Technologies | Phase 3 |
| Terminated | RENOVATE Fibrosis:HFNC Versus NIPPV in Acute Respiratory Failure in Patients With Pulmonary Fibrosis NCT04253405 | Hospital do Coracao | N/A |
| Unknown | Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge NCT04537130 | Instituto Oncológico Dr Rosell | Phase 1 |
| Completed | The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstit NCT04619680 | Icahn School of Medicine at Mount Sinai | Phase 4 |
| Unknown | BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients NCT04482595 | Humanetics Corporation | Phase 2 |
| Terminated | Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders NCT02748798 | Thunder Bay Regional Health Research Institute | EARLY_Phase 1 |
| Active Not Recruiting | Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibroti NCT04680832 | Erasmus Medical Center | — |
| Recruiting | A Non-pharmacological Cough Control Therapy NCT04767074 | West Park Healthcare Centre | N/A |
| Unknown | Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients NCT04517162 | Janette Furuzawa Carballeda | Phase 1 / Phase 2 |
| Completed | A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis NCT04308681 | Bristol-Myers Squibb | Phase 2 |
| Unknown | LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION NCT04409275 | Fundación para la Investigación del Hospital Clínico de Valencia | — |
| Completed | SVF for Treating Pulmonary Fibrosis Post COVID-19 NCT06304623 | Michael H Carstens | Phase 1 |
| Recruiting | An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using eHealth Technology NCT04304898 | Erasmus Medical Center | — |
| Unknown | Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19) NCT04416100 | Medical University Innsbruck | — |
| Completed | Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands NCT04488562 | Erasmus Medical Center | — |
| Active Not Recruiting | Pulmonary Fibrosis During Severe COVID-19 Pneumonia NCT04987528 | Hôpital Européen Marseille | — |
| Completed | Pulmonary Fibrosis After Severe COVID-19 Pneumonia NCT06423560 | IRCCS San Raffaele | — |
| Completed | A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulm NCT03727451 | Bellerophon | Phase 2 |
| Recruiting | Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Pa NCT03535545 | Massachusetts General Hospital | Phase 1 |
| Completed | Supporting Adherence to Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis NCT03567785 | KU Leuven | — |
| Recruiting | Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease NCT03455686 | McMaster University | N/A |
| Completed | Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies NCT03385668 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Unknown | A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonar NCT05747508 | Bellerophon | Phase 2 |
| Completed | Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan NCT03242759 | Boehringer Ingelheim | — |
| Unknown | Accuracy of Spircare Device as Compared to the Conventional Plethysmograph NCT03056066 | Spircare Ltd. | — |
| Unknown | Spanish Version of the KBILD Questionnaire NCT03103178 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | — |
| Unknown | Diagnostic Value of KL-6 in ILD NCT03103191 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | — |
| Completed | Computerized Lung Sound Analysis NCT02771184 | Smolle-Juettner Freyja, Prof MD | N/A |
| Withdrawn | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis NCT02603068 | United Therapeutics | Phase 2 |
| Completed | Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis NCT02510937 | Celgene | Phase 1 |
| Unknown | Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment NCT02496182 | Grupo Medifarma, S. A. de C. V. | Phase 2 / Phase 3 |
| Completed | Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome NCT02439528 | Hospices Civils de Lyon | N/A |
| Completed | Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease NCT02055222 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Effects of Pulmonary Rehabilitation on Functional and Health Status Measures in Pulmonary Fibrosis NCT03542318 | University of Malta | — |
| Recruiting | European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank NCT02852928 | Matthias Griese | — |
| Completed | Supplemental Oxygen in Pulmonary Fibrosis NCT01961362 | National Jewish Health | — |
| Completed | Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitab NCT01615484 | University of North Carolina, Chapel Hill | N/A |
| Completed | Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation NCT01916577 | University of Colorado, Denver | Phase 1 |
| Unknown | Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab NCT01917877 | Qingdao Central Hospital | Phase 2 |
| Completed | Assessment of Pulmonary Specialty Physicians' Approach to Advanced Care Planning in Patients With Chronic Pulm NCT01825538 | Jennifer McCallister MD | — |
| Completed | The Effectiveness of Pulmonary Rehabilitation on Saturation in Patients With Idiopathic Pulmonary Fibrosis NCT07031362 | Izmir Katip Celebi University | N/A |
| Completed | Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis NCT02594059 | Hopital Foch | N/A |
| Completed | Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis NCT02668029 | University of Siena | Phase 2 |
| Completed | Pulmonary Fibrosis and Telomerase Mutation Study NCT01501578 | Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires | — |
| Completed | Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174) NCT01417156 | Boehringer Ingelheim | Phase 2 |
| Completed | Clinical and Pathophysiological Investigations Into Erdheim Chester Disease NCT01417520 | National Human Genome Research Institute (NHGRI) | — |
| Completed | Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II NCT01335477 | Boehringer Ingelheim | Phase 3 |
| Completed | Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients NCT01335464 | Boehringer Ingelheim | Phase 3 |
| Terminated | A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF NCT01203943 | Celgene | Phase 2 |
| Terminated | Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability NCT01241942 | University of North Carolina, Chapel Hill | N/A |
| Completed | Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study NCT01271842 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Completed | Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF) NCT01170065 | Boehringer Ingelheim | Phase 2 |
| Completed | Explorative Study on the Molecular Pathology of Lung Fibrosis by Combination of Clinical Assessment and System NCT01687946 | Medical University of Vienna | — |
| Completed | Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema NCT01121367 | Beijing Chao Yang Hospital | — |
| Withdrawn | Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis NCT01135199 | Stanford University | Phase 2 |
| Completed | Comparative Study of 3 Portable Oxygen Concentrators During a 6-minute Walk Test in Patients With Chronic Lung NCT01653730 | Ottawa Hospital Research Institute | N/A |
| Completed | Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology NCT03462524 | St. James's Hospital, Ireland | — |
| Completed | Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF NCT00650091 | Duke University | Phase 3 |
| Terminated | Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis NCT00981747 | Alicia Gerke | Phase 2 / Phase 3 |
| Unknown | Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients NCT00896155 | Tata Memorial Hospital | Phase 3 |
| Completed | A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants W NCT00786201 | Centocor, Inc. | Phase 2 |
| Terminated | Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary NCT00690885 | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Phase 2 |
| Completed | Dyspnea in Patients With Pulmonary Fibrosis NCT00611182 | University of California, San Francisco | — |
| Completed | Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis NCT00514683 | Boehringer Ingelheim | Phase 2 |
| Completed | The Influence of Personality on Pulmonary Fibrosis and Sarcoidosis NCT00504621 | Maastricht University Medical Center | — |
| Completed | Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis NCT00517933 | Duke University | Phase 3 |
| Terminated | Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome NCT00467831 | National Human Genome Research Institute (NHGRI) | Phase 1 / Phase 2 |
| Unknown | Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis NCT00439543 | Interstitial Lung Disease Study Group, Korea | Phase 2 / Phase 3 |
| Completed | Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease NCT00911794 | Winthrop University Hospital | N/A |
| Completed | A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis NCT00563212 | NYU Langone Health | Phase 1 |
| Completed | Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases NCT00366509 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients NCT00455767 | Debiopharm International SA | Phase 2 |
| Recruiting | Explanted Lung Tissues With Pulmonary Fibrosis NCT00515567 | University of Chicago | — |
| Completed | Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome NCT00001596 | William Gahl, M.D. | Phase 2 |
| Completed | Using Health-related Quality of Life (HRQL) in Routine Clinical Care NCT00457301 | University of Alberta | — |
| Completed | Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis NCT00109681 | Actelion | Phase 2 |
| Completed | Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hyper NCT00352482 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Active Not Recruiting | Analysis of Specimens From Individuals With Pulmonary Fibrosis NCT00084305 | National Human Genome Research Institute (NHGRI) | — |
| Terminated | The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) NCT00075998 | InterMune | Phase 3 |
| Terminated | An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF NCT00076635 | InterMune | Phase 3 |
| Completed | Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis NCT00080223 | Genentech, Inc. | Phase 2 |
| Completed | Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma NCT00070590 | Actelion | Phase 2 / Phase 3 |
| Completed | Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study NCT00131274 | Daniels, Craig E., M.D. | Phase 2 / Phase 3 |
| Recruiting | Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF) NCT00258570 | University of Pittsburgh | — |
| Completed | An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) NCT00052052 | InterMune | Phase 2 |
| Terminated | A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b NCT00052039 | InterMune | Phase 3 |
| Active Not Recruiting | Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF) NCT00258544 | University of Pittsburgh | — |
| Completed | Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis NCT01442779 | Texas Tech University Health Sciences Center | Phase 2 |
| Completed | Linkage Study in Familial Pulmonary Fibrosis NCT00016627 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) NCT00639496 | Zambon SpA | Phase 3 |
| Completed | Scleroderma Lung Disease NCT00004563 | The University of Texas Health Science Center, Houston | Phase 3 |
| Completed | Lung Disease Associated With Rheumatoid Arthritis NCT00001876 | National Human Genome Research Institute (NHGRI) | — |
| Completed | Specimen Collection for Individuals With Lung Disease Associated With Rheumatoid Arthritis NCT00001884 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis NCT00001885 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Segmental Bronchoalveolar Lavage NCT00001618 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Recruiting | Role of Genetic Factors in the Development of Lung Disease NCT00001532 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Terminated | Idiopathic Pulmonary Fibrosis: a Case-control Study NCT00005295 | University of New Mexico | — |
| Completed | Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases NCT00005317 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Diffuse Fibrotic Lung Disease NCT00000596 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Available | Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis NCT05356052 | Bellerophon | — |
| Available | Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refra NCT04432545 | Universidad de la Sabana | — |
| Completed | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis NCT00063869 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 |